6XB3 Stock Overview
A clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Biophytis S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.65 |
52 Week High | €13.88 |
52 Week Low | €0.40 |
Beta | 1.11 |
1 Month Change | -20.73% |
3 Month Change | -26.14% |
1 Year Change | -91.07% |
3 Year Change | -99.84% |
5 Year Change | -99.84% |
Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Shareholder Returns
6XB3 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0.6% | -1.4% | -2.3% |
1Y | -91.1% | -23.0% | 1.0% |
Return vs Industry: 6XB3 underperformed the German Biotechs industry which returned -23% over the past year.
Return vs Market: 6XB3 underperformed the German Market which returned 1% over the past year.
Price Volatility
6XB3 volatility | |
---|---|
6XB3 Average Weekly Movement | 8.9% |
Biotechs Industry Average Movement | 4.2% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.4% |
10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 6XB3's share price has been volatile over the past 3 months.
Volatility Over Time: 6XB3's weekly volatility has decreased from 48% to 9% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 22 | Stanislas Veillet | www.biophytis.com |
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company’s lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19.
Biophytis S.A. Fundamentals Summary
6XB3 fundamental statistics | |
---|---|
Market cap | €1.72m |
Earnings (TTM) | -€17.03m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs 6XB3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6XB3 income statement (TTM) | |
---|---|
Revenue | €0 |
Cost of Revenue | €0 |
Gross Profit | €0 |
Other Expenses | €17.03m |
Earnings | -€17.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -5.95 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -207.8% |
How did 6XB3 perform over the long term?
See historical performance and comparison